Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. (Nasdaq: KURA) is a biopharmaceutical company focused on precision medicines for cancer, and its news flow reflects the evolution of this strategy. Company announcements highlight progress with KOMZIFTI (ziftomenib), an oral menin inhibitor approved in the United States for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options.
News items for KURA commonly cover regulatory milestones, clinical data and commercial updates. Recent releases describe full FDA approval of KOMZIFTI, its addition to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology as a Category 2A recommended option for relapsed or refractory NPM1-mutated AML, and the start of U.S. commercial sales. Kura also reports on its collaboration with Kyowa Kirin, including milestone payments tied to clinical and commercial events.
Investors following KURA news can expect detailed coverage of clinical trial readouts from programs such as KOMET-001, KOMET-007 and KOMET-017, which evaluate ziftomenib across newly diagnosed and relapsed or refractory AML, often in combination with regimens like cytarabine/daunorubicin and venetoclax/azacitidine. Additional news addresses the company’s farnesyl transferase inhibitor programs, darlifarnib and tipifarnib, and their activity in solid tumors.
Kura’s press releases also include corporate updates such as financial results, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in scientific and investor conferences. For readers tracking KURA, this news page offers a centralized view of key developments in its precision oncology pipeline, regulatory interactions, collaborations and commercialization activities.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Kura Oncology, a clinical-stage biopharmaceutical company focused on precision cancer treatments, will participate in Stifel's 2023 Targeted Oncology Days. CEO Troy Wilson is set to appear in a virtual fireside chat on April 25, 2023, at 1:00 p.m. ET. Investors can access a live audio webcast on Kura's website, with an archived replay available post-event.
Kura's pipeline includes ziftomenib, targeting NPM1-mutant relapsed or refractory acute myeloid leukemia (AML), currently in a Phase 2 trial. Additionally, tipifarnib is in a Phase 1/2 trial for PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC). Kura also plans to initiate trials for KO-2806, a next-gen therapy for advanced solid tumors.
Kura Oncology, Inc. (Nasdaq: KURA) announced promising preclinical data showing the potential of farnesyl transferase inhibitors (FTIs) to treat solid tumors. These findings were presented at the AACR Annual Meeting, highlighting the synergistic effects of tipifarnib combined with targeted therapies like KRASG12C inhibitors and TKIs. Kura plans to initiate the Phase 1 dose-escalation trial (FIT-001) of KO-2806, a next-generation FTI, later this year, focusing on its safety and effectiveness as a monotherapy and in combination therapies. The company aims for KO-2806 to address adaptive resistance mechanisms that limit the effectiveness of current targeted cancer therapies.
Kura Oncology (Nasdaq: KURA) announced the acceptance of two abstracts for presentation at the AACR Annual Meeting in Orlando, scheduled from April 14-19, 2023. The presentations will showcase preclinical data on combining farnesyl transferase inhibitors (FTIs) with KRASG12C inhibitors and tyrosine kinase inhibitors, which may help prevent resistance to targeted therapies. The company recently received FDA clearance for the Investigational New Drug application of KO-2806, a next-generation FTI, and plans to initiate the FIT-001 Phase 1 trial later this year.
SAN DIEGO, March 1, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, a clinical-stage biopharmaceutical company focused on precision cancer medicines, announced that CEO Troy Wilson will participate in several investor conferences. Key events include:
- A “Leukemia Corporate Panel” at the Cowen Health Care Conference in Boston on March 8, 2023, at 12:50 p.m. ET.
- A fireside chat at the Cowen Health Care Conference on the same day at 2:50 p.m. ET.
- A fireside chat at the Barclays Global Healthcare Conference in Miami on March 14, 2023, at 2:35 p.m. ET.
Live webcasts will be available on Kura's website, with archived replays post-event.
Kura Oncology reported promising Phase 1 data for ziftomenib, showing a 30% complete response (CR) rate among 20 patients with NPM1-mutant AML. Ziftomenib is now in a registration-directed trial (KOMET-001) aiming for up to 85 patients. The company has cleared the IND for KO-2806, its next-generation farnesyl transferase inhibitor. Kura received a $25 million investment from Bristol Myers Squibb, boosting its cash reserves to $438 million, sufficient to fund operations into Q4 2025. The company plans multiple combination trials for ziftomenib, marking potential growth in precision cancer medicine.